Replacing biologics and peptides with innovative, small molecule drugs.
Biologics and peptides have revolutionized healthcare – offering life-changing, breakthrough medicines to patients in desperate need. These highly innovative large molecules have now set the stage for a new generation of equally transformative orally available small molecule medicines. The global patient need remains immense, and with enhanced pharmaceutical properties, such as improved oral bioavailability, stability, easier logistics and reduced cost, small molecule medicines could address a market worth more than $300 billion annually.
THIS IS EXACTLY WHAT OUR TEAM AT STRUCTURE IS DRIVEN TO ACCOMPLISH.
DRUG DISCOVERY EXPERTISE
Harnessing structure-based drug design, coupled with our advanced computational technologies and world-class expertise, we are committed to converting biologics and peptides into life-changing small molecule medicines for everyone around the world.
Global solutions require global expertise. At Structure, we are led by an experienced group of drug hunters and industry leaders from around the world, including scientific experts who are renowned in the field of GPCR-targeted structure-based drug discovery. Our team includes pioneers in solving various G-protein coupled receptor (GPCR) protein structures, providing a strong foundation for tackling even the most difficult drug targets.
Head of Biology
Clinical Development Operations
Head of Biology
Structure Basecamp Bio
Board of Directors
Managing Partner, Potrero Hill Advisors
Johnson & Johnson